alendronate has been researched along with olpadronic acid in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, BN; Caldera, A; Croft, SL; Docampo, R; Grimley, JS; Heath, HT; Kendrick, H; Lewis, JC; Lira, R; Martin, MB; Moreno, SN; Oldfield, E; Urbina, JA; Yardley, V | 1 |
| Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
| Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Craig, SP; Delfino, JM; Fernández, D; Wenck, MA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Den Hartigh, J; Pas, O; Ramp-Koopmanschap, W; Twiss, IM; Vermeij, P | 1 |
| Bellido, T; Manolagas, SC; Parfitt, AM; Plotkin, LI; Roberson, PK; Weinstein, RS | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Gomez-Acotto, C; Mautalen, C; Zeni, S | 1 |
| Bosch, JJ; Burggraaf, J; Cohen, AF; de Kam, ML; Twiss, IM; van den Berk, AH; Vermeij, P | 1 |
1 review(s) available for alendronate and olpadronic acid
| Article | Year |
|---|---|
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
1 trial(s) available for alendronate and olpadronic acid
| Article | Year |
|---|---|
A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Diphosphonates; Female; Gastrointestinal Diseases; Humans; Pamidronate; Single-Blind Method | 2006 |
9 other study(ies) available for alendronate and olpadronic acid
| Article | Year |
|---|---|
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
Topics: Animals; Antiprotozoal Agents; Chlorocebus aethiops; Diphosphonates; Leishmania donovani; Plasmodium falciparum; Structure-Activity Relationship; Toxoplasma; Trypanosoma brucei brucei; Trypanosoma cruzi; Vero Cells | 2001 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2004 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
The purine transferase from Trypanosoma cruzi as a potential target for bisphosphonate-based chemotherapeutic compounds.
Topics: Animals; Diphosphonates; Drug Delivery Systems; Pentosyltransferases; Trypanosoma cruzi | 2004 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium.
Topics: Alendronate; Apoptosis; Caco-2 Cells; Calcium; Cell Survival; Diphosphonates; Epithelial Cells; Humans; Intestinal Mucosa; Models, Biological; Nitrogen; Pamidronate; Solubility; Structure-Activity Relationship | 1999 |
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.
Topics: Alendronate; Animals; Apoptosis; Calcitonin; Cell Line; Cells, Cultured; Dexamethasone; Diphosphonates; Etidronic Acid; Etoposide; In Situ Nick-End Labeling; Mice; Osteoblasts; Osteocytes; Pamidronate; Prednisolone; Skull; Tumor Necrosis Factor-alpha | 1999 |
Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats?
Topics: Alendronate; Animals; Body Weight; Bone Diseases, Metabolic; Diphosphonates; Female; Pamidronate; Rats; Rats, Sprague-Dawley; Thyroxine | 2001 |